A phase II open label clinical study of the safety, tolerability and efficacy of ILB(®) for Amyotrophic Lateral Sclerosis

INTRODUCTION: Amyotrophic lateral sclerosis (ALS) is an invariably lethal progressive disease, causing degeneration of neurons and muscle. No current treatment halts or reverses disease advance. This single arm, open label, clinical trial in patients with ALS investigated the safety and tolerability...

Descripción completa

Detalles Bibliográficos
Autores principales: Logan, Ann, Nagy, Zsuzsanna, Barnes, Nicholas M., Belli, Antonio, Di Pietro, Valentina, Tavazzi, Barbara, Lazzarino, Giuseppe, Lazzarino, Giacomo, Bruce, Lars, Persson, Lennart I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9132272/
https://www.ncbi.nlm.nih.gov/pubmed/35613082
http://dx.doi.org/10.1371/journal.pone.0267183

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9132272/
https://www.ncbi.nlm.nih.gov/pubmed/35613082
http://dx.doi.org/10.1371/journal.pone.0267183

Ejemplares similares